News

Tris Pharma Strengthens Its Branded Commercial Leadership Team

Published on September 04, 2019

Todd Killian to lead Market Access and Trade Relations
Scott Brunetto to lead Commercial Operations and Analytics

MONMOUTH JUNCTION, NJ, September 4, 2019 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the addition of two industry veterans to join its growing branded business. Todd Killian, Vice President, Market Access and Trade Relations, and Scott Brunetto, Vice President, Commercial Operations and Analytics, will lead critical functions supporting Tris’ growing portfolio of branded prescription ADHD medications which include Quillivant XR^® (methylphenidate HCl), QuilliChew ER^® (methylphenidate HCl) and Dyanavel XR^® (amphetamine). See Approved Use and Important Safety Information for these products, below.

Todd Killian will lead Tris’ account management, payer marketing, pricing, managed care contracting, distribution/pharmacy supply, and production planning. Todd is a proven market access leader and has spent a significant amount of time in roles of increasing responsibility at large and small specialty pharma companies including Pfizer, Merck, Allergan and Mallinckrodt Specialty Pharmaceuticals. Most recently Todd was Vice President and General Manager of Market Access, Pricing and Patient Services at Eaglet Specialty Pharmaceuticals.

Scott Brunetto will be responsible for commercial operations, analytics, market research and data purchasing and integrity. Scott joins Tris with over 25 years of experience in the pharmaceutical industry, with an emphasis on marketing and sales analytics, including marketing research, forecasting, competitive intelligence, promotion response modeling, sales force analysis and incentive compensation. His expertise encompasses commercialization, partnerships, acquisitions, and global product launches, across multiple in-line Rx and OTC brands. Prior to joining Tris, Scott served at Vice President, Commercial Operations at Synergy Pharmaceutics and held multiple leadership roles at Shire Pharmaceuticals, Johnson & Johnson and IMS Health.

“I am proud to have experienced and talented professionals such as Todd and Scott join our team to lead critical roles that enable us to grow and better serve the ADHD community,” said Tom Curatolo, Chief Commercial Officer of Tris Pharma. “Their deep functional experience and familiarity with the ADHD category ensure that we are well-prepared to serve patients with ADHD and support our growing portfolio of products.”

APPROVED USE

Dyanavel XR, Quillivant XR, and QuilliChew ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older. These medicines may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Dyanavel XR, Quillivant XR, and QuilliChew ER are safe and effective in children under 6 years of age.

IMPORTANT SAFETY INFORMATION

Dyanavel XR, Quillivant XR, and QuilliChew ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep these medicines in a safe place to prevent misuse and abuse. Selling or giving away these medicines may harm others and is against the law. Tell your doctor if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Dyanavel XR, or Quillivant XR and QuilliChew ER, should not be taken if you or your child are allergic to amphetamine or methylphenidate hydrochloride, respectively, or any of the ingredients in these medicines, or are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.

Dyanavel XR, Quillivant XR, and QuilliChew ER can cause serious side effects. Tell the doctor:

if you or your child have heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in children 6 to 17 years old with heart problems or defects, and sudden death, stroke, and heart attack have happened in adults. Your doctor should check you or your child carefully for heart problems before starting any of these medicines. Since increases in blood pressure and heart rate may occur, the doctor should regularly check these during treatment. Call the doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking any of these medicines.
if you or your child have mental problems, or a family history of suicide, bipolar illness, or depression. This is important because new or worsening behavior and thought problems or bipolar illness may occur. New symptoms such as seeing or hearing things that are not real, believing things that are not true, being suspicious, or having new manic symptoms may occur. Call the doctor right away if there are any new or worsening mental symptoms during treatment.
if you or your child have circulation problems in fingers and toes (called peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature, and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking Dyanavel XR, Quillivant XR, or QuilliChew ER.
if your child is having slowing of growth (height and weight); Your child should have his or her height and weight checked often while taking Dyanavel XR, Quillivant XR, or QuilliChew ER.
if you or your child develop painful and prolonged erections (priapism), seek medical help right away. Priapism has occurred with methylphenidate (Quillivant XR and QuilliChew ER). Because priapism can cause long-lasting damage, it should be checked by a doctor right away.
if you or your child have symptoms of serotonin syndrome – agitation, hallucinations, coma, or other changes in mental status; fast heartbeat; sweating or fever; nausea, vomiting, diarrhea; high or low blood pressure; problems controlling movements or muscle twitching; muscle stiffness or tightness. Serotonin syndrome may occur when Dyanavel XR is taken with certain other medicines and may be life-threatening. Stop Dyanavel XR and call your doctor or go to the nearest hospital emergency room.
if you or your child have phenylketonuria (PKU). QuilliChew ER contains phenylalanine as part of the artificial sweetener, aspartame. The artificial sweetener may be harmful to people with PKU or who are allergic to phenylalanine.
if you or your child are pregnant or plan to become pregnant. It is not known if Dyanavel XR, Quillivant XR, or QuilliChew ER will harm your unborn baby. Tell your doctor if you or your child become pregnant during treatment with any of these medicines.
if you or your child is breastfeeding or plan to breastfeed. Dyanavel XR, Quillivant XR, and QuilliChew ER pass into breast milk. You or your child should not breastfeed while you are taking any of these medicines.

Common side effects of amphetamine products include:

dry mouth
decreased appetite
weight loss
stomach pain
nausea
trouble sleeping
restlessness
extreme mood changes
dizziness
increased heart rate

Common side effects of methylphenidate products include:

decreased appetite
trouble sleeping
nausea
vomiting
indigestion
stomach pain
weight loss
anxiety
dizziness
irritability
mood swings
fast heart beat
increased blood pressure

Talk to your doctor if you or your child have any side effects that bother you or do not go away.

Avoid drinking alcohol while taking Dyanavel XR, Quillivant XR, or QuilliChew ER.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

See Full Prescribing Information and Medication Guide for Dyanavel XR, Quillivant XR, and QuilliChew ER, including Boxed Warning about Abuse and Dependence.

About ADHD

ADHD is one of the most common neurodevelopmental disorders characterized by an ongoing pattern of inattention and/or hyperactivity and impulsivity. These behaviors can interfere with functioning or development. According to the Centers for Disease Control and Prevention’s 2011 data, 11 percent of children aged four to 17 years in the U.S. have received an ADHD diagnosis at some point in their life.

About Tris Pharma

Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that address unmet patient needs. Tris has pioneered the delivery of sustained release in the liquid, chewable, orally disintegrating tablet, and strip dosage forms that benefit a wide variety of patients and their unique needs. Tris’ research, manufacturing and commercial facilities are located in Central New Jersey.

For more information, please visit staging.trispharma.com

DYANAVEL is a registered trademark of Tris Pharma, Inc.

Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc.

CONTACT INFORMATION
FOR INFORMATION
Cheryl Patnick (732) 823-4940
cpatnick@trispharma.com